Fig. 7
XMU-MP-2 promotes the chemosensitivity of CRC in vivo. A XMU-MP-2 suppresses the weight and volume of the subcutaneous tumors formed by PTK6 overexpression CRC cells. Both the weight and volume of subcutaneous tumor were shown in the right panel (mean ± SD, n = 5). B Western blot assays indicate that XMU-MP-2 can inhibit the PTK6 induced activation of STAT3 signaling and the expression of stem cell markers in the subcutaneous tumors. C CCK8 assays show that XMU-MP-2 can further inhibit L-OHP suppressed proliferation of CRC cells (mean ± SD, n = 3). D The orthotopic xenograft tumor model reveals that XMU-MPX-2 can prolong the overall survival of the L-OHP treated tumor-bearing mice (mean ± SD, n = 7). E The construction process of patient-derived xenograft (PDX) tumors. F XMU-MP-2 suppresses the weight and volume of the PDX tumors derived from CASE1 in the L-OHP treated tumor-bearing mice. Both the volume and weight of subcutaneous tumor were shown in the right panel (mean ± SD, n = 6). G IHC staining indicates that XMU-MP-2 can reduce the phosphorylation of PTK6 and the stem cell markers in the PDX tumors derived from CASE1. *P < 0.05, **P < 0.01, ***P < 0.001, # indicates P > 0.05